STOCK TITAN

VAXXINITY INC A - VAXX STOCK NEWS

Welcome to our dedicated page for VAXXINITY A news (Ticker: VAXX), a resource for investors and traders seeking the latest updates and insights on VAXXINITY A stock.

Vaxxinity, Inc. (Nasdaq: VAXX) is a pioneering biotechnology company committed to transforming the healthcare landscape through innovative active immunotherapy solutions. Headquartered in Cape Canaveral, Florida, Vaxxinity focuses on developing synthetic peptide-based vaccines to treat and prevent chronic diseases, including Alzheimer's disease, Parkinson's disease, hypercholesterolemia, and migraines. The company's proprietary technology platform enables the creation of cost-effective, scalable, and convenient immunotherapies that challenge the traditional monoclonal antibody treatment model.

One of Vaxxinity's flagship projects is UB-311, an active immunotherapy targeting toxic beta-amyloid oligomers and fibrils associated with Alzheimer's disease. Recent Phase 2a clinical trials published in The Lancet's eBioMedicine confirm that UB-311 is safe and well-tolerated, with promising trends in slowing cognitive decline. Unlike FDA-approved monoclonal antibodies that require biweekly IV infusions and are costly, UB-311 offers a more convenient intramuscular injection with fewer side effects, making it more accessible and affordable for patients.

Another notable project is UB-312 for Parkinson's disease, which targets aggregated alpha-synuclein. Data from Phase 1 trials show UB-312's potential in reducing pathological alpha-synuclein in cerebrospinal fluid, marking a significant step forward in Parkinson's treatment. Vaxxinity is also developing VXX-401 for lowering LDL cholesterol, with promising preclinical results that demonstrate sustained reductions in LDL-C levels.

Vaxxinity's commitment to democratizing healthcare extends to its COVID-19 vaccine program, UB-612, designed to serve as a heterologous booster. The company's collaboration with renowned institutions like the University of Florida and UCF highlights its focus on advancing immunotherapies for neurodegenerative diseases and space health research.

Financially, Vaxxinity has managed to reduce its net loss year-over-year, reflecting strategic cost management and operational efficiencies. The company is positioning itself for significant milestones, including potential regulatory approvals and further clinical advancements. With a strong leadership team and a clear vision, Vaxxinity is set to make a historic impact on global health.

Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) CEO to Present Company Update at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
conferences
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) announced its participation in three upcoming medical and investor conferences in November. The company's scientists and executives will present their findings, including the novel peptide/protein subunit COVID-19 vaccine booster UB-612, which stimulated broadly neutralizing and Fc-mediated effector antibodies in a Phase 3 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.18%
Tags
conferences
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) reported Q3 2023 financial results and a corporate update. The company made progress with clinical programs for Parkinson's and Alzheimer's diseases, and hypercholesterolemia. They also announced a potential COVID-19 booster and additions to the executive team. Financially, Vaxxinity had $42.5 million in liquid assets as of September 30, 2023, and a net loss of $13.1 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
Rhea-AI Summary
Vaxxinity CEO to present at investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.09%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.1%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags

FAQ

What is the current stock price of VAXXINITY A (VAXX)?

The current stock price of VAXXINITY A (VAXX) is $0.0002 as of November 20, 2024.

What is the market cap of VAXXINITY A (VAXX)?

The market cap of VAXXINITY A (VAXX) is approximately 13.9M.

What does Vaxxinity, Inc. specialize in?

Vaxxinity specializes in developing synthetic peptide-based vaccines to treat and prevent chronic diseases such as Alzheimer's, Parkinson's, and hypercholesterolemia.

What is UB-311?

UB-311 is an active immunotherapy developed by Vaxxinity that targets toxic beta-amyloid oligomers and fibrils to treat Alzheimer's disease.

How does UB-312 help Parkinson's disease patients?

UB-312 targets aggregated alpha-synuclein, with clinical trials showing potential reductions in pathological alpha-synuclein levels in Parkinson's disease patients.

What are the advantages of Vaxxinity's vaccines?

Vaxxinity's vaccines offer convenience, cost-effectiveness, and lower side effects compared to traditional monoclonal antibody treatments.

What recent achievements has Vaxxinity made?

Recent achievements include Phase 2a trial data for UB-311, Phase 1 trial data for UB-312, and preclinical success with VXX-401 in lowering LDL cholesterol.

What is the focus of Vaxxinity's COVID-19 vaccine program?

Vaxxinity's COVID-19 vaccine program, UB-612, is designed as a heterologous booster to enhance immune responses against COVID-19 variants.

How does Vaxxinity collaborate with other institutions?

Vaxxinity collaborates with institutions like the University of Florida and UCF to advance research in neurodegenerative diseases and space health.

What are Vaxxinity's financial highlights?

Vaxxinity has reduced its net loss year-over-year, reflecting strategic cost management and operational efficiencies as it advances its clinical programs.

Who leads Vaxxinity, Inc.?

Vaxxinity is led by CEO Mei Mei Hu and Executive Chairman Lou Reese, supported by a team of experienced industry veterans.

What is Vaxxinity's long-term vision?

Vaxxinity aims to democratize healthcare by providing accessible, cost-effective, and innovative immunotherapy solutions for chronic diseases globally.

VAXXINITY INC A

Nasdaq:VAXX

VAXX Rankings

VAXX Stock Data

13.95M
55.66M
50.71%
0.08%
3.33%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EXPLORATION PARK